1
|
Halsby K, Dobler G, Easton A, Karelis G, Krbková L, Kyncl J, Sellner J, Strle F, Veje M, Zajkowska J, Zavadska D, Angulo FJ, Pilz A, Erber W, Gabriel M, Russo J, Price M, Madhava H, Meyding-Lamadé UK. Evaluating the need for standardised disease manifestation categories in patients infected with the tick-borne encephalitis virus: A Delphi panel. Ticks Tick Borne Dis 2024; 16:102431. [PMID: 39708718 DOI: 10.1016/j.ttbdis.2024.102431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2024] [Revised: 11/07/2024] [Accepted: 12/15/2024] [Indexed: 12/23/2024]
Abstract
Categorization systems for tick-borne encephalitis virus (TBEV) infection lack consistency in classifying disease severity. To evaluate the need for a standard, consensus-based categorisation system for TBEV infection across subtypes, we gathered an expert panel of clinicians and scientists with diverse expertise in TBEV infection. Consensus was sought using the Delphi technique, which consisted of 2 web-based survey questionnaires and a final, virtual, consensus-building exercise. Ten panellists representing 8 European countries participated in the Delphi exercise, with specialities in neurology, infectious disease, paediatrics, immunology, virology, and epidemiology. Panellists reached unanimous consensus on the need for a standardised, international categorisation system to capture both clinical presentation and severity of TBEV infection. Ideally, such a system should be feasible for use at bedside, be clear and easy to understand, and capture both the acute and follow-up phases of TBEV infection. Areas requiring further discussion were (1) the timepoints at which assessments should be made and (2) whether there should be a separate system for children. This Delphi panel study found that a critical gap persists in the absence of a feasible and practical classification system for TBEV infection. Specifically, the findings of our Delphi exercise highlight the need for the development of a user-friendly classification system that captures the acute and follow-up (i.e., outcome) phases of TBEV infection and optimally reflects both clinical presentation and severity. Development of a clinical categorisation system will enhance patient care and foster comparability among studies, thereby supporting treatment development, refining vaccine strategies, and fortifying public health surveillance.
Collapse
Affiliation(s)
- Kate Halsby
- Vaccines and Antivirals Medical Affairs, Pfizer Ltd, Surrey, United Kingdom.
| | - Gerhard Dobler
- Bundeswehr Institute of Microbiology, Munich, Germany; Department of Infectious Diseases and Tropical Medicine, University Munich, Germany
| | - Ava Easton
- Encephalitis International, North Yorkshire, United Kingdom; Institute of Infection, Veterinary and Ecological Science, University of Liverpool, NIHR HPRU for Emerging and Zoonotic Infection, Liverpool, United Kingdom
| | - Guntis Karelis
- Rīga Stradiņš University, Dzirciema St. 16, Rīga, LV-1007, Latvia; Rīga East University Hospital, Hipokrata St. 2, Rīga, LV-1079, Latvia
| | - Lenka Krbková
- Department of Pediatric Infectious Diseases, Faculty of Medicine, Masaryk University and Faculty Hospital, Brno, Czech Republic
| | - Jan Kyncl
- Department of Infectious Diseases Epidemiology, National Institute of Public Health, Srobarova 49, Prague, Czech Republic; Department of Epidemiology and Biostatistics, Third Faculty of Medicine, Charles University, Ruska 87, Prague, Czech Republic
| | - Johann Sellner
- Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Affiliated with Karl Landsteiner University of Health Sciences, Krems, Austria
| | - Franc Strle
- Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia
| | - Malin Veje
- Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy at Gothenburg University, Guldhedsgatan 10, 41346, Gothenburg, Sweden
| | - Joanna Zajkowska
- Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, Białystok 15-540, Poland
| | - Dace Zavadska
- Riga Stradins University, Department of Paediatrics, Children Clinical University Hospital, Riga, Vienibas gatve 45, Riga, LV1004, Latvia
| | - Frederick J Angulo
- Vaccines and Antivirals Medical Affairs, Pfizer Biopharma Group, 500 Arcola Rd, Collegeville, PA,19426, United States
| | - Andreas Pilz
- Vaccines and Antivirals Medical Affairs, Pfizer Corporation Austria, Vienna, Austria
| | - Wilhelm Erber
- Vaccines and Antivirals Medical Affairs, Pfizer Corporation Austria, Vienna, Austria
| | - Meghan Gabriel
- RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC, United States
| | - Jon Russo
- RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC, United States
| | - Mark Price
- RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC, United States
| | - Harish Madhava
- Vaccines and Antivirals Medical Affairs, Pfizer Ltd, Surrey, United Kingdom
| | | |
Collapse
|
2
|
Halsby K, Gildea L, Madhava H, Angulo FJ, Pilz A, Erber W, Moisi J, Schley K, Colosia A, Sellner J. Clinical manifestations and outcomes of Tick-borne encephalitis: A systematic literature review. Ticks Tick Borne Dis 2024; 15:102407. [PMID: 39500220 DOI: 10.1016/j.ttbdis.2024.102407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Revised: 07/31/2024] [Accepted: 10/06/2024] [Indexed: 12/17/2024]
Abstract
Tick-borne encephalitis (TBE) is caused by a viral infection and can lead to acute and persistent damage to the central and peripheral nervous systems. Recently, the incidence of TBE in Europe has risen, and epidemiological patterns of disease have changed, emphasising the need for improved understanding of this vaccine-preventable disease. Although TBE is endemic in many countries, the disease spectrum of TBE is not well described. We sought to characterise the clinical manifestations and outcomes of TBE by estimating the proportions of TBE patients with each type of manifestation and the risk of adverse outcomes for children and adults separately. A systematic literature review was conducted on 2 August 2022 for articles published in any language since 1 January 2007. Additional relevant studies were found in reference lists of identified articles. The review was limited to countries where only the European subtype of TBEV circulates. Of the 1,632 unique titles and abstracts identified and reviewed, 21 were retained for data analysis. The 21 studies were split into a main analysis (15 studies reporting patients hospitalised with laboratory-confirmed TBE) and a secondary analysis (6 studies reporting hospitalised and non-hospitalised patients who sought medical treatment for laboratory-confirmed TBE). The main analysis included 5,012 adults and 640 children. The predominant clinical manifestation in adults was encephalitis (61 %), followed by meningitis (33 %), radiculitis (14 %), and myelitis (6 %) (the manifestations were evaluated independently, so they will not sum to 100 %). With outliers removed, similar proportions of adults had encephalitis (48 %) and meningitis (44 %). Among cases in children, meningitis (77 %) was the most common manifestation, whereas encephalitis (23 %) and myelitis (1.3 %) were less frequent. Among hospitalised patients with TBE, the proportion of intensive care unit (ICU) admissions and deaths were similar for adults (15.5 % and 0.9 %, respectively) and children (16.4 % and 0 %, respectively.) The percentage of patients with sequelae when examined >12 months from acute TBE was 39.5 % for adults and 16.2 % for children. The evidence was challenging to aggregate due to study heterogeneity, variability in categorising clinical manifestations of central nervous system disease, variability of denominator populations, and differences in healthcare systems and diagnostic practices across countries. Our study disclosed distinct patterns of clinical manifestation among hospitalised adult and child patients with TBE and a high proportion of ICU admissions and long-term neurological sequelae across both age groups. These findings reinforce the continued need for preventive measures in the populations at risk. Moreover, variability of study admission criteria, including difficulty with clinical manifestation categorisation, calls for a more standardised approach to summarising TBE manifestations and outcomes across Europe.
Collapse
Affiliation(s)
- Kate Halsby
- Vaccines, Antivirals, and Evidence Generation, Pfizer, UK.
| | - Liesl Gildea
- Market Access and Outcomes Strategy, RTI Health Solutions, UK
| | - Harish Madhava
- Vaccines, Antivirals, and Evidence Generation, Pfizer, UK
| | | | - Andreas Pilz
- Vaccines, Antivirals, and Evidence Generation, Pfizer, Austria
| | - Wilhelm Erber
- Vaccines, Antivirals, and Evidence Generation, Pfizer, Austria
| | - Jennifer Moisi
- Vaccines, Antivirals, and Evidence Generation, Pfizer, France
| | | | - Ann Colosia
- Market Access and Outcomes Strategy, RTI Health Solutions, US
| | - Johann Sellner
- Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria
| |
Collapse
|
3
|
Garibashvili T, Kämpchen K, Heckmann JG. Image in clinical medicine : Scapular winging in tick-borne encephalitis. Wien Klin Wochenschr 2024; 136:478-479. [PMID: 38315207 DOI: 10.1007/s00508-024-02330-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Accepted: 01/14/2024] [Indexed: 02/07/2024]
Affiliation(s)
- Tamara Garibashvili
- Department of Neurology, Municipal Hospital Landshut, Robert-Koch Str. 1, 84034, Landshut, Germany
| | - Katharine Kämpchen
- Department of Neurology, Municipal Hospital Landshut, Robert-Koch Str. 1, 84034, Landshut, Germany
| | - Josef G Heckmann
- Department of Neurology, Municipal Hospital Landshut, Robert-Koch Str. 1, 84034, Landshut, Germany.
| |
Collapse
|
4
|
Fareed A, Rohail S, Zameer U, Wahid A, Akhtar SMM, Masood W. A comprehensive neurological perspective on tick-borne flaviviruses, with emphasis on Powassan virus. Ther Adv Infect Dis 2024; 11:20499361241247470. [PMID: 38693969 PMCID: PMC11062229 DOI: 10.1177/20499361241247470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 03/28/2024] [Indexed: 05/03/2024] Open
Abstract
Powassan virus (POWV), a tick-borne flavivirus transmitted primarily by Ixodes ticks, poses a significant threat as it can lead to severe neuroinvasive illness. This review delves into the nuanced clinical presentation of Powassan infection, a challenge in diagnosis exacerbated by the absence of an available vaccine. Over the past decade, the prevalence of POWV has surged in North America, necessitating a thorough examination of its neurological manifestations alongside tick-borne encephalitis virus (TBEV). A comprehensive literature search conducted up to January 2024 revealed 135 cases of neurological symptoms associated with either Powassan or TBEV infection. Notably, severe occipital headache emerged as the most prevalent symptom (22.75%), followed by meningoencephalitis (10.34%), seizures (8.27%), and flaccid paresis (6.8%). Additional manifestations included poor balance, wide gait, dysarthria, facial nerve palsy, seizure, slurred speech, and absent deep tendon reflexes. Tragically, nine cases resulted in fatal outcomes attributed to POWV infection. This analysis highlights the intricate spectrum of neurological symptoms associated with Powassan infection and underscores the necessity for heightened awareness among medical practitioners, particularly in regions with a higher prevalence of the virus. The complexity of symptoms emphasizes the need for further research to unravel the factors contributing to this diversity. Additionally, exploring potential treatment avenues and vaccine development is crucial in addressing the rising threat posed by POWV, ultimately enhancing our ability to manage and prevent severe neurological outcomes.
Collapse
Affiliation(s)
- Areeba Fareed
- Department of Medicine, Karachi Medical and Dental College, Block M, North Nazimabad, Karachi 74600, Pakistan
| | - Samia Rohail
- Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
| | - Ushna Zameer
- Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
| | - Abdul Wahid
- Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
| | | | - Waniyah Masood
- Department of Medicine, Dow Medical College, Karachi, Pakistan
| |
Collapse
|